The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
INVO Fertility (IVF) received a formal notice from Nasdaq on April 23, 2026, regarding non-compliance with listing rules due to the delayed filing of its annual Form 10-K. The company attributed this delay to complex accounting matters that hindered the timely submission of financial statements to the SEC. With a market capitalization of approximately $3.1 million, IVF is currently not generating profits and faces significant operational losses. Furthermore, the company received a low GF Score of 29/100, signaling substantial financial and profitability challenges. These developments place additional pressure on the firm to regain compliance under Listing Rule 5250(c)(1) to avoid potential delisting. Market participants are closely monitoring management's ability to resolve these accounting issues and stabilize its fragile financial position.
Sign in to access this content
Sign In